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ABSTRACT
Objective: We investigated the risk of gastric cancer among men with Helicobacter pylori (H. pylori)
infection or atrophic gastritis (AG) in a 15-year follow-up.
Materials and methods: Study population consists of 12,016 men aged 50–65 years at the beginning
of the follow-up in 1994–1996. Serum levels of pepsinogen I (SPGI) and antibodies (IgG) to H. pylori
(HpAb) were assayed from serums collected in 1994–1996. Incidence of gastric cancer in the study
population was assessed in follow-up from 1994 to 2011 by data from the nationwide cancer registry.
Based on SPGI and HpAb values, standardized incidence ratios (SIRs) of gastric cancer were calculated
in three subgroups, that is, in those with a healthy stomach, those with H. pylori infection but without
AG and those with AG. Risk ratios (RR) of gastric cancer were calculated using SIR of subgroups.
Results: During 15 years, seven gastric cancers appeared per 79,928 person years among men with
healthy stomachs, 50 cancers per 92,533 person years in men with H. pylori infection but without AG,
and 8 per 8658 person years in men with AG. Risk ratio (RR) of stomach cancer in men with H. pylori
infection was 5.8 (95%CI: 2.7–15.3) compared to men with healthy stomachs, and 9.1 (95%CI: 2.9–30.0)
in men with AG. There were no differences in cancer risk between cardia and distal stomach.
Conclusions: Risk of gastric cancer is low in men with healthy stomachs. It is significantly increased in
those with H. pylori infection and more in those with AG.
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Atrophic gastritis (AG) and acid-free stomach, which is either
autoimmune or a consequence of Helicobacter pylori (H. pylori)
infection, are risk conditions for stomach cancer, for the
cancer of an intestinal type in particular.[1–8] Less is known
about the magnitude of cancer risks in subjects with healthy
stomach mucosa or in those with only nonatrophic H. pylori
infection, although the H. pylori infection was classified as a
class 1 carcinogen by WHO/IARC already in 1994.[1]
The H. pylori infection causes chronic gastritis that is
initially nonatrophic, but it may later develop into various
forms and stages of atrophic gastritis and may end up as an
acid-free stomach.[6–9] Like AG, the nonatrophic form of H.
pylori gastritis is likely a precancerous condition, particularly
for gastric cancer of the diffuse type.[1,3,10]
In the present study, we investigated the long-term risk of
gastric cancer in a large population-based sample of men
with or without H. pylori infection or AG. The study popula-
tion consisted of 12,016 men representing the general male
population from two Finnish cities and was collected from
men who participated in a serum pepsinogen I (SPGI) screen-
ing study in 1994–1996. Thereafter, the men were followed
for 15 years, and gastric cancers in the study population
during follow-up were identified from the nationwide cancer
registry. The status of gastric mucosa in all 12,016 men was
assessed with biomarker tests for SPGI and antibodies (IgG)
to H. pylori (HpAb) from serum samples collected in
1994–1996. Based on the biomarker assays, we could classify
the study population into three subgroups; that is, those with
a healthy and normal gastric mucosa, those with pure H.
pylori infection (chronic nonatrophic gastritis) and those with
moderate or severe atrophic gastritis.
The main objective of this study was to estimate the risk
of gastric cancer due to only H. pylori infection; that is, in
chronic gastritis that is caused by H. pylori but not yet pro-
gressed to the atrophic stage. The other objectives were to
estimate the risk of gastric cancer in men with healthy stom-
ach mucosa, and to look at whether the H. pylori related risk
of gastric cancer varies between cancers in gastric cardia and
distal stomach.
Methods
Study population and the study cohorts
Initially, 16,872 men (50–65 years old) from two Finnish cities
were identified from the population registry and were invited
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to give a blood sample for the SPGI test, half in the autumn
of 1994 and half in the autumn of 1996 [11] (Table 1).
Altogether, 12,016 men (71%) participated and form the study
population in the present investigation. Among participants,
the serum levels of pepsinogen I (SPGI) and H. pylori antibod-
ies (IgG) (HpAb) were assayed from blood samples collected
in 1994–1996 to determine the presence or absence of an
ongoing H. pylori infection (chronic gastritis) and the presence
or absence of a moderate or severe stage of atrophic gastritis
in the stomach. The HpAb assays were done in 2012–2013
from the same serum samples from which the SPGI tests
were done already in 1994–1996.
Blood sampling and tests for SPGI and H. pylori
antibodies
Fasting sera were collected in aprotinin (Trasylol, Bayer
Germany; 200 KIE/mL) containing Venoject tubes and stored
at 70 C until analyzed. SPGI was analyzed in 1994–1996
using the specific enzyme-linked immunosorbent assay
(ELISA) tests provided by Biohit Healthcare Plc, Helsinki,
Finland. The assay has been calibrated to correspond to
results obtained by radioimmunoassay (RIA) used by Samloff
[12] using 238 serum samples with serum pepsinogen con-
centrations between 1.5 and 120lg/L. The sensitivity and
specificity of the SPGI test for advanced (moderate or severe)
atrophic gastritis are 92% and 90% at a cutoff level of 30 lg/
L, respectively, according to the manufacturers kit instructions
for use. In clinical practice and in endoscopy and biopsy hist-
ology controlled trials, the SPGI cutoff level of 25 lg/L has
been demonstrated to be a reliable criterion in exclusion,
inclusion or delineation of cases regarding the presence or
absence of advanced (moderate or severe) atrophic corpus
gastritis.[13–15] Therefore, the level of 25 lg/L was also
selected as a cutoff criterion for SPGI in the present study. In
addition, this cutoff corresponds with the SPGI levels of
assays initially specified by Samloff.[12]
The HpAb assay was done in 2012–2013 by the ELISA test
provided by Biohit Healthcare Plc, Helsinki, Finland, and was
performed according to the instructions of the manufacturer.
The sensitivity and specificity of the test to detect the
ongoing H. pylori infection are 93% and 96%, respectively,
according to an independent analysis and report of AFSSAPS
(Agence Francaise de Securite Sanitaire des Produits de
Sante) on commercial H. pylori ELISA test kits in 2008.
The serum levels of SPGI and HpAb were used as criteria in
the classification of the study population into three subcohorts
(subgroups). The SPGI levels of 25lg/L or more (25þ) were
considered to exclude the cases with advanced (moderate or
severe) atrophic gastritis in the stomach, irrespective of the
cause of atrophic gastritis (autoimmunity or H. pylori ori-
gin).[14–16] The HpAb levels 30 EIU or more (30þ) were con-
sidered to indicate an ongoing H. pylori infection (gastritis).[17]
Classification into three subgroups was as follows (Table 1):
Healthy. Men with normal and healthy stomach mucosa: SPGI
25 lg/L or higher (SPGI 25þ) and HpAb lower than 30 EIU (HpAb
<30).
H. pylori infection. Men with only H. pylori infection (gastritis)
without moderate or severe atrophic gastritis (AG), and without an
acid free stomach: SPGI 25 lg/L or higher (SPGI 25þ) and HpAb
30 EIU or more (HpAb 30þ).
Atrophic gastritis. Men with moderate or severe atrophic gastritis
in the gastric corpus or fundus (SPGI <25lg/L), irrespective of the
presence or absence of an ongoing H. pylori infection. The
atrophic gastritis can be either autoimmune (HpAb negative) or of
H. pylori origin (HpAb positive).
Follow-up and recording of the cancer incidence data in
1994–2011
Information about cancer cases during the follow-up from
1994 to 2011 was received in 2012 from the Finnish Cancer
Registry (FCR). Due to mandatory reporting of all cancer diag-
noses in Finland, the FCR has a national coverage of over
99% of all new cancer cases in Finland.[16] The follow-up
began on 1 December 1994 for the first half of the men and
on 1 November 1996 for the second half of the men (one
Table 1. Follow-up data for total study population and three subgroups, and on referral actions carried out in men from 1994–1996 to 2011.
Biomarker test
Persons Person Actions and tests
Subgroup SPG1lg/L HpAb (IgG) Number Years Carried out in each group
Healthy 25þ <30 5232 79,928 SPG1 assayed in 1994–1996
HpAb status assayed in 2014 from
serum samples taken in 1994–1996
No active clinical interventions in 1994–1996
H. pylori infection 25þ 30þ 6178 92,533 SPG1 assayed in 1996–1996
HpAb status assayed in 2014
from serum samples taken in 1994–1996
No active clinical interventions in 1994–1996
Atrophic gastritis <25 any 606 8658 SPG1 assayed in 1994–1996
HpAb status assayed in 2014 from serum samples taken in 1994–1996
All referred in 1994–1996 to consultation, treatment, endoscopies and surveillance
in local hospitals or health care centers
Whole sample any any 12,016 181,118 All 16,872 men born 1929–1949 in two cities were invited to the SPG1 test in
1994–1996
12,016 men could be tested for SPG1 and HpAb (IgG) status from same serum sam-
ples taken in 1994–1996
SPG1 was assayed in 1994–1996 and HpAb status in 2014
Follow-up of the study cohort from 1994 to 2011 by Finnish Cancer Registry
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month after finishing SPGI screening) and ended on 31
December 2011).
The cancer registry includes data on all invasive cases of
cancer. It does not include data on cases classified as nonin-
vasive (preneoplastic lesions, dysplasia or intramucosal neo-
plasia). Information from the FCR provided data on the
subsite of cancer in the stomach. Therefore, the analyses
could be performed separately for cases in which the cancer
was located in the distal stomach (pylorus, antrum, angulus,
corpus or fundus) or in the gastric cardia.
In calculating the standardized incidence ratios (SIRs), the
age-standardized incidence of cancer in the total male popu-
lation of Finland (expected rates) were compared with the
observed incidence rates of cancer in the subcohorts. The
expected number of cancers for each age group (5-year age
categories) and 4-year calendar period were estimated by
multiplying the number of person years in the category accu-
mulated in the subcohorts with the respective incidence rate
in the total male population at the same age in Finland. The
standardized incidence rates were calculated according nor-
mal procedures of age standardization.[17] The 95% confi-
dence intervals (CI) were calculated on the basis of standard
error of SIR [15] and these were estimated assuming a
Poisson distribution for the number of observed cancers. The
p values of the differences between SIRs were calculated on
the basis of confidence intervals.[18,19]
The authors had official permission for collection of the
data and for carrying out the present investigation by linking
the laboratory test results with the information from FCR
(Dnro THL/1349/5.05.00/2009).
Results
Altogether, 65 gastric cancer cases appeared in 15 years in
the present study population. Of these, only seven (11%)
occurred in men with a healthy stomach (without H. pylori
infection or AG) mucosa at the time of drawing the blood
sample (1994–1996).
Table 2 presents the observed and expected cumulative
incidence of gastric cancer in three subgroups during the 15-
year follow-up period. Results on the incidence of cancer sep-
arately in the distal stomach and gastric cardia are provided.
In addition, Table 2 presents the SIRs of gastric cancer and
the SIR of total cancer (all malignant diseases) in each sub-
group and in the whole-study cohort.
We found the SIR for gastric cancer among men with
healthy stomachs to be significantly lower than the corre-
sponding SIR among men with H. pylori infection (SIR 0.21,
95% CI: 0.04–0.60) and lower than among the whole study
cohort (Table 3).
Table 3 provides information on incidences of gastric cancer
and on SIRs according to different lengths of follow-up time
during the 15-year study period. A similarly low SIR of gastric
cancer was evident among men with healthy stomachs over
the whole 15 years of follow-up. Among men with H. pylori
infection (gastritis), the incidence of gastric cancer tended to
increase with the length of follow-up time. The SIR of gastric
cancer was significantly (p< 0.05) increased among men in the
H. pylori infection group, followed up to 10 years or more.
The risk ratio (RR) of gastric cancer between those with H.
pylori infection and men with healthy stomachs was 5.8. The
RR between those with AG compared to those with H. pylori
infection was 1.6 (0.6–3.3), and 9.1 (2.9–30.0) as compared to
men with healthy gastric mucosa. The risk ratios were quite
constant regardless of the sub-site of gastric cancer (Table 4).
Table 2. Cancer registry based observed and expected incidence and SIR of
gastric cancer in three subgroups and in whole study population during the fol-
low-up from 1994–1996 to 2011.
Subgroup, cancer
type and site SPG1lg/L
HpAb
(IgG) Obs. Exp. SIR 95%SD
Healthy 25þ <30
Gastric cancer
Distal stomach 5 25 0.20 0.01–0.39
Cardia 2 7 0.29 0.01–0.73
Stomach, all sites 7 32 0.22a 0.04–0.40
Total cancer, any site 1403 1341 1.05 0.97–1.16
H. pylori infection 25þ 30þ
Gastric cancer
Distal stomach 37 31 1.19 0.62–1.76
Cardia 13 8 1.63 0.19–3.06
Stomach, all sites 50 39 1.28 0.75–1.82
Total cancer, any site 1692 1642 1.03 0.96–1.13
Atrophic gastritis <25 any
Gastric cancer
Distal stomach 6 3 2.00 0.01–4.77
Cardia 2 1 2.00 0.01–6.80
Stomach, all sites 8 4 2.00 0.01–4.40
Total cancer, any site 167 165 1.01 0.79–1.32
Whole sample any any
Gastric cancer
Distal stomach 48 60 0.80 0.50–1.10
Cardia 17 15 1.13 0.35–1.92
Stomach, all sites 65 75 0.87 0.58–1.15
Total cancer, any site 3262 3146 1.04 0.99–1.10
ap¼ 0.009.
Table 3. Cancer registry based observed and expected incidence and SIR of
gastric cancer in three subgroups in different time periods of follow-up from
1994–1996 to 2011.
Subgroup, cancer
type and site SPG1lg/L
HpAb
(IgG) Obs. Exp. SIR 95%SD
Healthy 25þ <30
Gastric cancer
Follow-up 0–2 years 1 3 0.33 0.01–1.62
Follow-up 2–9 years 3 14 0.21a 0.04–0.62
Follow-up 10þ years 3 14 0.21a 0.04–0.62
H. pylori infection 25þ 30þ
Gastric cancer
Follow-up 0–2 years 4 4 1.00 0.25–2.32
Follow-up 2–9 years 17 17 1.00 0.57–1.55
Follow-up 10þ years 29 17 1.71 0.68–2.72
Atrophic gastritis <25 any
Gastric cancer
Follow-up 0–2 years 2 0.5 4.00 0.50–14.83
Follow-up 2–9 years 2 2 1.00 0.13–3.97
Follow-up 10þ years 4 2 2.37 0.65–6.06
Whole sample any any
Gastric cancer
Follow-up 0–2 years 7 8 0.88 0.32–1.73
Follow-up 2–9 years 22 33 0.67 0.41–1.00
Follow-up 10þ years 36 34 1.06 0.75–1.48
Total cancer
Follow-up 0–2 years 215 214 1.00 0.87–1.14
Follow-up 2–9 years 1384 1325 1.04 0.99–1.08
Follow-up 10þ years 1663 1608 1.03 0.99–1.07
ap¼ 0.025.
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Discussion
Altogether, 65 gastric cancers developed in the whole study
population of 12,016 men during the 15-year follow-up
period, of which only 7 (11%) cancers developed in men with
healthy stomach mucosa (5232 men). The SIR of gastric can-
cer in the subgroup of men with healthy stomachs was nearly
80% lower than expected, and the RR of SIRs was approxi-
mately six times higher in those with H. pylori infection com-
pared to men with a healthy stomach. Thus, the people with
healthy stomach mucosa are clearly those who have the low-
est risk of gastric cancer known so far.
The present observation also demonstrates that an H.
pylori infection alone (nonatrophic H. pylori gastritis) is by
itself a clear risk condition for gastric cancer as was suggested
by the IARC/WHO statement in 1994.[1] The observation indi-
cates that the simple infection markedly increases the cancer
risk when compared to a healthy stomach. Supporting the
conclusions of H. pylori infection as a risk condition for gastric
cancer, the SIR of gastric cancer among men with H. pylori
infection tended to rise during follow-up. Practically, a half
(29 of 50) of gastric cancers in the H. pylori subgroup
appeared during the last 5-year period (10þ years).
We authors consider the estimates of SIRs and RRs of gas-
tric cancer in the present subgroups of ‘Healthy stomach
mucosa’ or ‘H. pylori infection without AG’ to be reliable and
epidemiologically valid. The delineation of men into sub-
groups was based on biomarker tests that are highly reliable
in reflecting the health of stomach mucosa and enable nonin-
vasive tests of large populations of asymptomatic people with
a simple method.[17–20] Furthermore, the gastric cancers
identified during the follow-up period were based on cancer
cases recorded by nationwide cancer registry with coverage
of over 99% of all cancer cases in Finland.[16] In addition, the
subgroups followed up in the present investigation were
derived from the study population that represents the general
population of males who were 50–65 years old at the begin-
ning of the follow-up and were living in two cities in south-
ern Finland in 1994–1996.[11]
All men in the subgroups of healthy gastric mucosa or H.
pylori infection without AG had normal levels of SPGI in
1994–1996. No referral to treatment, clinical surveillance or
other actions were carried out by the investigators fpr any-
one, and all men were passively followed up by the cancer
registry during the 15-year follow-up period from 1994 to
2011.[11] In addition, the delineation of the men to those
with healthy stomach mucosa and to those with nonatrophic
H pylori gastritis was done with the HpAb test (from serum
samples collected in 1994–1996) only at the end of the
follow-up period. However, unknown confounders may still
exist that may contribute to estimates of cancer risks in the
study subgroups. For example, differences in smoking, dietary
habits, alcohol consumption, socioeconomic status or eradica-
tion of H. pylori during the 15-year follow-up among thou-
sands of men in each subgroup, could not be controlled for
in the present investigation. However, these possible biases,
even though certainly existing, can hardly explain the differ-
ences observed in the gastric cancer risk between men with
healthy gastric mucosa and those with H. pylori infection.
On the other hand, the observed SIRs and RRs of gastric
cancer are likely severely biased in the present study in the
subgroup of men with AG; that is, in the group of 606 men
who had moderate or severe atrophic gastritis in gastric cor-
pus and fundus by the SPGI test in 1994–1996. All these men
had a low (<30 lg/L) serum level of pepsinogen I (SPGI) and
were, therefore, considered to have a hypochlorhydric or
even achlorhydric stomach in 1994–1996; that is, a severely
sick and atrophic stomach mucosa considered to be a prema-
lignant condition that needs special attention.[1–5] Therefore,
all these men were actively referred in 1994–1996 for medical
consultation, treatment and clinical surveillance in specialized
hospitals or health care centers.[11]
Possible endoscopic, surgical, therapeutic or preventive
interventions carried out among the 606 men with AG may
decrease the incidence of gastric cancer in the 15-year follow-
up.[11] Therefore, the observed incidences and SIRs of gastric
cancer in this subgroup of men are likely underestimations of
the real cancer risk. The authors were not able to explore the
procedures that were done to these 606 men with AG during
the 15-year follow-up period. In spite of this, the RR of gastric
cancer was approximately 9 in the subgroup of men with AG
as compared to men with healthy stomach mucosa.
In the present study, the RR of cancers in the gastric cardia
was 5.4 in men with H. pylori seropositivity as compared to
cardia cancers in subjects with healthy stomach mucosa. The
SIR of cardia cancers was also quite similar (1.6 vs. 1.3) to that
of distal gastric cancer in men with H. pylori seropositivity.
Even though the number of cases is low, and even though
the risk estimates are insignificant, the observations support
the view that the H. pylori infection associates with cardia
cancers similarly as with gastric cancers in the distal stomach.
The observations of H. pylori infection as an etiological fac-
tor for cancer of the gastric cardia have been contradictory.
In contrast to the present observations, some studies indicate
that cardia adenocarcinomas do not associate with H. pylori
infection and that the pathogenesis of these cancers resem-
bles the pathogenesis of lower esophageal adenocarcinomas
in patients with gastroesophageal reflux disease (GERD).[20]
Differences in pathogenesis of cardia and noncardia gastric
carcinomas have been proposed.[21–25]
In the past, several prospective investigations with
case–control design have been published on the risk of
gastric cancer due to H. pylori infection. In a systematic
review covering 10 studies before 1998, including approxi-
mately 800 gastric cancer cases, the analysis yielded a RR
of 2.5 (95%CI: 1.9–3.4) for gastric cancer in H. pylori-sero-
positive people.[26] An European prospective case–control
study of 233 gastric cancers and 910 controls, including
Table 4. The risk ratios (RR) and CI95% of risk ratios of gastric cancer between











Distal stomach 6.0 (2.3–19. 0) 1.7 (0.6–4.0) 10.0 (2.5–41.0)
p¼ 0.001 p¼ 0.276 p¼ 0.001
Cardia 5.7 (1.3–52.0) 1.2 (0.1–5.4) 7.0 (0.5–97.0)
p¼ 0.064 p¼ 0.867 p¼ 0.148
Stomach, all sites 5.8 (2.7–15.3) 1.6 (0.6–3.3) 9.1 (2.9–30.0)
p¼ 0.000 p¼ 0.283 p¼ 0.000
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the SPGI assay in addition to the H. pylori test, yielded a
RR of 6.5 (95%CI: 3.3–12.6) for noncardia gastric cancer in
subjects infected with a cytotoxic (CagA) H. pylori strain.[27]
In a prospective Finnish study, the RR of gastric cancer was
3.1 (95%CI: 1.97–4.95) between H. pylori infected and non-
infected persons.[28] The RR, based on case–control study
designs, varied between 1.6 and 7.9 in three published
papers from two extensive prospective nutritional interven-
tion trials of over 29,000 males at age of 50–69 years in
Linxian, China and Finland.[23–25]
Our estimate of the risk of gastric cancer due to H. pylori
infection, 5.8 (95%CI: 2.7–15.3), is similar or somewhat higher
than the published risks estimated in the above-mentioned
prospective investigations. In contrast to the mentioned
case–control investigations, the risk estimates for gastric can-
cer in the present study were received from all new cases of
gastric cancer that appeared during the follow-up time in all
subgroups of men without ongoing H. pylori infection or AG,
and those with a verified ongoing H. pylori infection or AG at
beginning of the follow-up.[11]
Differences in the magnitude of the observed risk of
gastric cancer between the present and earlier published
investigations may be due to differences in the study
design, in the application of biomarker tests for defining H.
pylori infection or AG, or in the criteria of the subjects who
are classified as having healthy gastric mucosa or AG. All
subjects with a negative H. pylori test do not have healthy
gastric mucosa and therefore cannot be classified as
healthy controls. Helicobacter pylori negative cases are, on
the other hand, often considered healthy, even though
their stomachs are, in fact, severely sick. In an earlier
Finnish study among subjects with endoscopically verified
atrophic gastritis, an ongoing H. pylori infection was found
only in 82% of cases with the serological H. pylori test.[29]
Thus, without controlling for SPGI, the H. pylori seronegative
cases with AG are easily misclassified into the subgroup of
people with normal and healthy gastric mucosa. On the
other hand, the cases with H. pylori-seropositive AG and
acid-free stomach may be erroneously classified as cases
with a simple uncomplicated H. pylori infection.
We conclude that the present investigation emphasizes
the following: of all gastric cancers that occurred during the
15-year follow-up among elderly men, only 11% appeared in
men with healthy stomachs. The risk of stomach cancer is
approximately six times higher among men with H. pylori
infection than among men with healthy stomach mucosa,
and the H. pylori infection raises the gastric cancer risk simi-
larly in the gastric cardia and in other sites of the stomach.
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